This article is more than 5 years old. Information may no longer be current.

FDA grants fast track designation to CB-839 for metastatic kidney cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA granted fast track designation to CB-839 for use in combination with everolimus for the treatment of patients with metastatic renal cell carcinoma who received at least two prior lines of therapy, according to the drug’s manufacturer.

An ongoing phase 1/phase 2 study is designed to evaluate CB-839 (Calithera Biosciences) — a first-in-class, oral, selective, potent glutaminase inhibitor — in combination with everolimus (Afinitor, Novartis). The trial includes patients with solid tumors, including renal cell carcinoma, triple-negative breast cancer, non-small cell lung cancer and melanoma.

“We are pleased that CB-839 has been granted fast track designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our glutaminase inhibitor as an important new therapy for patients with relapsed renal cell carcinoma,” Susan Molineaux, PhD, president and CEO of Calithera, said in a company-issued press release.

The company plans to initiate a global, randomized trial of the combination this year, Molineauz added.